Vimarsana
Biggest News Aggregation in the World

Secondary Endpoints News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Secondary Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Secondary Endpoints Today - Breaking & Trending Today

Dermavant Sciences: Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD - Vimarsana News

Dermavant Sciences: Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD

- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity - Vimarsana News

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight...

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress - Vimarsana News

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with...

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial ... - Vimarsana News

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial ...

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis

Neuraptive Therapeutics Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX001 for the Adjunct Treatment of Transected Peripheral Nerves - Vimarsana News

Neuraptive Therapeutics Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX001 for the Adjunct Treatment of Transected Peripheral Nerves

Neuraptive Therapeutics Inc. a leader in nerve repair and regeneration is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries.